



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P O Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

22830

7590

01/02/2009

CARR & FERRELL LLP  
2200 GENG ROAD  
PALO ALTO, CA 94303

EXAMINER

FRENEAU, VANEL

ART UNIT

PAPER NUMBER

3687

DATE MAILED: 01/02/2009

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/616,472

07/14/2000

Whitney Durand

PA4507US

6507

TITLE OF INVENTION: SYSTEM, APPARATUS, AND METHODS FOR DEVELOPING AND DELIVERING HEALTH INFORMATION

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$755	\$0	\$0	\$755	04/02/2009

**THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.** THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

**THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.** SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

## HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

**IMPORTANT REMINDER:** Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

# **PART B - FEE(S) TRANSMITTAL**

**Complete and send this form, together with applicable fee(s), to: Mail**

**Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

22830 7590 01/02/2009

**CARR & FERRELL LLP  
2200 GENG ROAD  
PALO ALTO, CA 94303**

## **Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE-FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/616,472 07/14/2000 Whitney Durand PA4507US 6507

**TITLE OF INVENTION: SYSTEM, APPARATUS, AND METHODS FOR DEVELOPING AND DELIVERING HEALTH INFORMATION**

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$755	\$0	\$0	\$755	04/02/2009

EXAMINER	ART UNIT	CLASS-SUBCLASS
FRENEL, VANEL	3687	705-002000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/147; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

1

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2

3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY AND STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee  
☐ Publication Fee (No small entity discount permitted)  
☐ Advance Order - # of Copies \_\_\_\_\_

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.  
☐ Payment by credit card. Form PTO-2038 is attached.  
☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number \_\_\_\_\_ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature \_\_\_\_\_ Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_ Registration No. \_\_\_\_\_

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/616,472	07/14/2000	Whitney Durand	PA4507US	6507
22830	7590	01/02/2009	EXAMINER	
CARR & FERRELL LLP 2200 GENG ROAD PALO ALTO, CA 94303			FREINEL, VANEL	
			ART UNIT	PAPER NUMBER

3687

DATE MAILED: 01/02/2009

## Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 234 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 234 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

**Notice of Allowability****Application No.**

09/616,472

**Examiner**

VANEL FRENEL

**Applicant(s)**

DURAND, WHITNEY

**Art Unit**

3687

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERIT IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 9/12/08 and Examiner's Amendment.
2. ☒ The allowed claim(s) is/are 175-186 and 199-208.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of the:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  
1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.  
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.  
**Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date 20080912
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_.

/Matthew S Gart/  
Supervisory Patent Examiner, Art Unit 3687

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

The following statement of reasons for allowance is in response to a request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission IDS filed on 9/12/08 has been entered.

## **EXAMINER'S AMENDMENT**

The application has been amended as follows: Claim 204 line 1, "the system of claim 202" is replaced to --the method of claim 202 --. Appropriate correction is required.

### **Amendment to the claims**

This listing of claims will replace all prior versions and listings of claims in this application:

1-174. (Canceled).

175. (Currently amended) A method of providing a plurality of participants with an ability to effect choices about future care of said participants, said method comprising;

receiving from an input user, via an interactive user interface accessible through an interact connection, raw data relevant to the future care of a participant should said participant prior to death become incapacitated;

providing via said interface guidance information comprising at least one input form, said at least one input form comprising electives available to said participant regarding said future care, and reference information associated with said available electives; analyzing said available electives in response to input by said input user to provide via said interface analysis information regarding said future care to allow informed choices of said electives to be made;

receiving from said input user via said interface at least one election of at least one of said electives;

providing said input user an identification instrument comprising a unique identification parameter corresponding to said participant;

storing in a computer-readable registry end-of-life information and said unique identification parameter in a form of an information set corresponding to said participant, said end-of-life .information comprising said received raw data and said at least one election;

receiving a request from an output user identifying an occurrence of an incapacitated state in said participant;

verifying that said request includes said unique identification parameter;

if so, generating an information product derivative of said information set comprising said participant's election corresponding to said incapacitated state, said information

product being generated in a form that is enforceable in a jurisdiction from which said request was received; and  
communicating said information product to an output recipient.

176. (Previously presented) The method of claim 175, wherein said analysis information is selected from the group consisting off a. a measurement of an outcome for at least one of said participant's choices regarding care; b. a prediction of an outcome for at least one of said participant's choices regarding care; c. a comparison of alternative choices regarding said participant's care; and d. interaction of drugs identified by participant in said end-of-life information.

177. (Previously presented) The method of claim 175, wherein said first providing step further comprises providing a second input form to said user for subsequent submission.

178. (Currently amended) The ~~[[system]]~~ method of claim 177, wherein said second input form is selected from a group consisting of an executable document and an election form.

179. (Previously presented) The method of claim 175, wherein said end-of-life information is selected from a group consisting of:  
a. an authorization to rely on a copy of an original document;

- b. an authorization to rely on a summary of an original document;
- c. a designation of at least one medication;
- d. a designation of at least one allergy;
- e. a designation of at least one health condition;
- f. a designation of at least one person to be contacted in case of emergency;
- g. a designation of at least one physician;
- h. emergency health information;
- i. an end-of-life choice;
- j. an advance directive;
- k. a Do-Not-Resuscitate Order;
- l. a document signed by a physician concerning medical care associated with an end-of-life condition;
- m. an authorization to donate an organ;
- n. output recipient information;
- o. enforcement information;
- p. medical information; and
- q. a portion of an item selected from the group a through p, above.

180. (Currently amended) The [[system]] method of claim 179, wherein[[,.]] when said end-of-life information is an end-of-life choice, said end-of-life choice is a choice selected from the group consisting of:

- a. a palliative care choice;



- b. a comfort care choice;
- c. a residence choice;
- d. a religious choice; and
- e. a spiritual choice.

181. (Currently amended) The [[system]] method of claim 179 wherein[[[,] when said end- of-life information is an advance directive, said advance directive is an advance directive selected from the group consisting of:

- a. a living will;
- b. a medical power of attorney;
- c. a selection of an end-of-life condition response;
- d. a selection of medical treatment; and
- e. a refusal of medical treatment.

182. (Previously presented) The method of claim 175, wherein said guidance information comprises:

- a designation of at least one end-of-life condition; and
- a designation of at least one end-of-life condition response, wherein said input user can choose at least one of said at least one end-of-life response for response to at least one of said at least one end-of-life condition.

183. (Previously presented) The method of claim 175, wherein said information product is selected from a group consisting of:

- a. an authorization to rely on a copy of an original document;
- b. an authorization to rely on a summary of an original document;
- c. a designation of at least one medication;
- d. a designation of at least one allergy;
- e. a designation of at least one health condition;
- f. a designation of at least one person to be contacted in case of emergency.
- g. a designation of at least one physician;
- h. emergency health information;
- i. an end-of-life choice;
- j. an advance directive;
- k. a Do-Not-Resuscitate Order;
- l. a document signed by a physician concerning medical care associated with an end-of-life condition;
- m. an authorization to donate an organ;
- n. output recipient information;
- o. enforcement information;
- p. medical information;
- q. a summary of an information product selected from the group consisting of a through p, above;
- r. a copy of an information product selected from the group consisting of a

through q, above; and

s. a report concerning said end-of-life information.) The method of claim 175, wherein said information set comprises said end-of-life information stored in a standardized form.

185. (Previously presented) The method of claim 184, wherein said generating step comprises translating said information set into an information product in a language other than that native to said input user.

186. (Previously presented) The method of claim 184, wherein said generating step comprises generating an information product legally enforceable in a jurisdiction other than that in which said participant resides.

187-198. (Cancelled)

199. (Currently amended) A method of providing a participant with an ability to effect choices about future care of said participant should said participant prior to death become incapacitated, said method comprising:  
providing via an interactive user interface accessible through an internet connection guidance information comprising at least one input form, said at least one input form comprising electives available to said participant regarding said future care, and reference information associated with said available electives;

analyzing said available electives in response to input by said input user to provide via said interface analysis information regarding said future care to allow informed choices of said electives to be made;

receiving from said input user via said interface at least one election of at least one of said electives;

storing in a computer-readable registry end-of-life information in a form of an information set corresponding to said participant, said end-of-life information comprising said at least one election;

upon receiving a request from an output user identifying an occurrence of an incapacitated state in said participant, generating an information product derivative of said information set comprising said participant's election corresponding to said incapacitated state; and

communicating said information product to an output recipient.

200. (Previously presented) The method of claim 199, wherein said analysis information is selected from a group consisting of:

- a. a measurement of an outcome for at least one of said participant's choices regarding care;
- b. a prediction of an outcome for at least one of said participant's choices regarding care;
- c. a comparison of alternative choices regarding said participant's care; and

d. interaction of drugs identified by participant in said end-of-life information.

201. (Previously presented) The method of claim 199, further comprising providing a second input form to said user for subsequent submission, wherein said input form is selected from the group consisting of an executable document and art election form.

202. (Currently amended) The method of claim 199, wherein said end-of-life information is selected from the group consisting of:

- a. an end-of-life choice;
- b. an advance directive;
- c. a Do-Not-Resuscitate Order; and
- d. an authorization to donate art organ[[:]].

203. (Currently amended) The [[system]] method of claim 202, wherein[[:]] when said end-of-life information is art end-of-life choice, said end-of-life choice is a choice selected from the group consisting of:

- a. a palliative care choice;
- b. a comfort care choice;
- c. a residence choice;
- d. a religious choice; and
- e. a spiritual choice.

204. (Currently amended) The system of claim 202 wherein[[,]] when said end-of-life information is an advance directive, said advance directive is an advance directive selected from the group consisting of:

- a. a living will;
- b. a medical power of attorney,
- c. a selection of an end-of-life condition response;
- d. a selection of medical treatment; and
- e. a refusal of medical treatment.

205. (Previously presented) The method of claim 199, wherein said guidance information comprises:

- a designation of at least one end-of-life condition; and
- a designation of at least one end-of-life condition response, wherein said input user can choose at least one of said at least one end-of-life response for response to at least one of said at least one end-of-life condition.

206. (Previously presented) The method of claim 199, wherein said information product is selected from a group consisting of:

- a. an end-of-life choice;
- b. an advance directive;
- c. a Do-Not-Resuscitate Order;
- d. an authorization to donate an organ;

- e. a summary of an information product selected from the group consisting of a through d, above;
- f. a copy of an information product selected from the group consisting of a through e, above; and
- g. a report concerning said end-of-life information.

207. (Previously presented) The method of claim 199, wherein said generating step comprises translating said information set into an information product in a language other than that native to said input user.

208. (Previously presented) The method of claim 199, wherein said generating step comprises generating an information product legally enforceable in a jurisdiction other than that in which said participant resides.

#### **Notice to Applicant**

This communication is in response to the RCE filed on 9/12/08. Claims 1-74, 187-198 have been cancelled. Claims 175, 178, 180-181, 199 and 202-204 have been amended. Claims 175-186 and 199-208 are pending.

#### **Allowable Subject Matter**

Claims 175-186 and 199- 208 are allowed. The following is an examiner's statement of reasons for allowance and in light of Applicant's arguments.

Independent claims 175 and 199 are directed to "analyzing said available electives in response to input by said input user to provide via said interface analysis information regarding said future care to allow informed choices of said electives to be made; receiving from said input user via said interface at least one election of at least one of said electives; providing said input user an identification instrument comprising a unique identification parameter corresponding to said participant; storing in a computer-readable registry end-of-life information and said unique identification parameter in the form of an information set corresponding to said participant, said end-of-life information comprising said received raw data and said at least one election; receiving a request from an output user identifying the occurrence of an anticipated state in said participant; verifying that said request includes said unique identification parameter; if so, generating an information product derivative of said information set comprising said participant's election corresponding to said incapacitated state, said information product being generated in a form that is enforceable in the jurisdiction from which said request was received; and communicating said information product to an output recipient".

The closest prior art of record, Perry et al. (5,241,466) discloses system for administering a central depository for living wills and other associated information. Mindrum (6,340,978) discloses method and apparatus for recording and presenting life stories.

Krim (2002/0072925) discloses posthumus communication. However, none of the cited prior fairly teaches/suggests "analyzing said available electives in response to input by said input user to provide via said interface analysis information regarding



said future care to allow informed choices of said electives to be made; receiving from said input user via said interface at least one election of at least one of said electives; providing said input user an identification instrument comprising a unique identification parameter corresponding to said participant; storing in a computer-readable registry end-of-life information and said unique identification parameter in the form of an information set corresponding to said participant, said end-of-life information comprising said received raw data and said at least one election; receiving a request from an output user identifying the occurrence of an anticipated state in said participant; verifying that said request includes said unique identification parameter; if so, generating an information product derivative of said information set comprising said participant's election corresponding to said incapacitated state, said information product being generated in a form that is enforceable in the jurisdiction from which said request was received; and communicating said information product to an output recipient", as recited in claims 175 and 199 above.

Claims 176-186 and 200-208 incorporate the features of claims 175 and 199 through their dependencies, and are also allowed for the same reasons given above.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to VANEL FRENEL whose telephone number is (571)272-6769. The examiner can normally be reached on 6:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Matthew S. Gart can be reached on 571-272-3955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Vanel Frenel/

Examiner, Art Unit 3687

November 24, 2008

/Matthew S Gart/

Supervisory Patent Examiner, Art Unit 3687

